Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer

Show full item record



Permalink

http://hdl.handle.net/10138/333053

Citation

Eurola , A , Ristimäki , A , Mustonen , H , Nurmi , A-M , Hagström , J , Haglund , C & Seppänen , H 2021 , ' Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer ' , Scientific Reports , vol. 11 , no. 1 , 9896 . https://doi.org/10.1038/s41598-021-89134-2

Title: Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer
Author: Eurola, Annika; Ristimäki, Ari; Mustonen, Harri; Nurmi, Anna-Maria; Hagström, Jaana; Haglund, Caj; Seppänen, Hanna
Contributor: University of Helsinki, CAN-PRO - Translational Cancer Medicine Program
University of Helsinki, Department of Pathology
University of Helsinki, HUS Abdominal Center
University of Helsinki, CAN-PRO - Translational Cancer Medicine Program
University of Helsinki, HUSLAB
University of Helsinki, HUS Abdominal Center
University of Helsinki, CAN-PRO - Translational Cancer Medicine Program
Date: 2021-05-10
Language: eng
Number of pages: 11
Belongs to series: Scientific Reports
ISSN: 2045-2322
URI: http://hdl.handle.net/10138/333053
Abstract: Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC. Through immunohistochemistry, we evaluated podocalyxin expression in 88 neoadjuvant and 143 upfront surgery patients using two antibodies. We developed a six-tier grading scheme for neoadjuvant responses evaluating the remaining tumor cells in surgical specimens. Strong podocalyxin immunopositivity associated with poor survival in the patients responding poorly to the neoadjuvant treatment (HR 4.16, 95% CI 1.56-11.01, p=0.004), although neoadjuvant patients exhibited generally low podocalyxin expression (p=0.017). Strong podocalyxin expression associated with perineural invasion (p=0.003) and lack of radiation (p=0.036). Two patients exhibited a complete neoadjuvant response, while a strong neoadjuvant response (
Subject: HUMAN PROTEIN ATLAS
POOR-PROGNOSIS
DUCTAL ADENOCARCINOMA
MAJOR SIALOPROTEIN
EXPRESSION
SURVIVAL
CHEMORADIOTHERAPY
CHEMORADIATION
GEMCITABINE
VALIDATION
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s41598_021_89134_2.pdf 1.314Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record